Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials

Background Patients with severe hypertriglyceridaemia (sHTG) are often refractory to lipid‐lowering therapy. Apolipoprotein (Apo) CIII inhibition could be promising to treat subjects with sHTG. The antisense oligonucleotide against APOC3 mRNA volanesorsen was recently introduced to treat sHTG. We pe...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical investigation 2022-11, Vol.52 (11), p.e13841-n/a
Main Authors: Calcaterra, Ilenia, Lupoli, Roberta, Di Minno, Alessandro, Di Minno, Matteo Nicola Dario
Format: Article
Language:English
Subjects:
Antisense oligonucleotides
Antisense RNA
Apolipoprotein B-48
Apolipoprotein C-III
apolipoprotein CIII
Apolipoproteins
Cholesterol, LDL
Clinical trials
Effectiveness
familial chylomicronaemia syndrome
hereditary lipid disorder
High density lipoprotein
Humans
Hyperlipidemias - drug therapy
Hypertriglyceridemia - drug therapy
Lipids
Lipoproteins (very low density)
Low density lipoprotein
Meta-analysis
mRNA
Oligonucleotides
Oligonucleotides, Antisense - therapeutic use
Patients
Placebos
Randomized Controlled Trials as Topic
Reduction
RNA, Messenger
Safety
severe hypertriglyceridaemia
Systematic Review
Systematic Reviews
Triglycerides
volanesorsen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Patients with severe hypertriglyceridaemia (sHTG) are often refractory to lipid‐lowering therapy. Apolipoprotein (Apo) CIII inhibition could be promising to treat subjects with sHTG. The antisense oligonucleotide against APOC3 mRNA volanesorsen was recently introduced to treat sHTG. We performed a systematic review and meta‐analysis of RCTs on the efficacy and safety of volanesorsen as compared to placebo treatment in patients with severe HTG. Methods Studies were systematically searched in the PubMed, Web of Science and Scopus databases according to PRISMA guidelines. The last search was performed on 7 February 2022. Results Four studies showed significant reduction in TG after 3 months of treatment with volanesorsen as compared with placebo (MD: −73.9%; 95%CI: −93.5%, −54.2; p 
ISSN:0014-2972
1365-2362
DOI:10.1111/eci.13841